Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
MOREPEN LABS ACTAVIS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
MOREPEN LABS Mar-23 |
ACTAVIS Dec-18 |
MOREPEN LABS/ ACTAVIS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 55 | 16,136 | - | |
Low | Rs | 24 | 10,824 | - | |
Sales per share (Unadj.) | Rs | 27.7 | 3,958.1 | - | |
Earnings per share (Unadj.) | Rs | 0.8 | -1,274.9 | - | |
Cash flow per share (Unadj.) | Rs | 1.3 | 417.1 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 14.7 | 16,325.5 | - | |
Shares outstanding (eoy) | m | 511.17 | 332.60 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.4 | 3.4 | 41.5% | |
Avg P/E ratio | x | 51.8 | -10.6 | -490.3% | |
P/CF ratio (eoy) | x | 30.1 | 32.3 | 93.1% | |
Price / Book Value ratio | x | 2.7 | 0.8 | 322.5% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 20,051 | 4,483,446 | 0.4% | |
No. of employees | `000 | NA | 16.9 | 0.0% | |
Total wages/salary | Rs m | 1,547 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 77,898.1 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | -25,091.0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 14,175 | 1,316,478 | 1.1% | |
Other income | Rs m | 61 | 25,175 | 0.2% | |
Total revenues | Rs m | 14,237 | 1,341,653 | 1.1% | |
Gross profit | Rs m | 795 | 34,498 | 2.3% | |
Depreciation | Rs m | 279 | 562,766 | 0.0% | |
Interest | Rs m | 20 | 75,968 | 0.0% | |
Profit before tax | Rs m | 558 | -579,060 | -0.1% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 147,684 | 0.0% | |
Tax | Rs m | 171 | -7,338 | -2.3% | |
Profit after tax | Rs m | 387 | -424,038 | -0.1% | |
Gross profit margin | % | 5.6 | 2.6 | 214.1% | |
Effective tax rate | % | 30.6 | 1.3 | 2,417.3% | |
Net profit margin | % | 2.7 | -32.2 | -8.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 7,562 | 539,950 | 1.4% | |
Current liabilities | Rs m | 3,212 | 477,658 | 0.7% | |
Net working cap to sales | % | 30.7 | 4.7 | 648.5% | |
Current ratio | x | 2.4 | 1.1 | 208.3% | |
Inventory Days | Days | 18 | 20 | 92.5% | |
Debtors Days | Days | 678 | 66 | 1,022.2% | |
Net fixed assets | Rs m | 3,543 | 149,018 | 2.4% | |
Share capital | Rs m | 1,022 | 0 | - | |
Net worth | Rs m | 7,529 | 5,429,856 | 0.1% | |
Long term debt | Rs m | 9 | 1,912,049 | 0.0% | |
Total assets | Rs m | 11,105 | 8,488,101 | 0.1% | |
Interest coverage | x | 29.1 | -6.6 | -440.1% | |
Debt to equity ratio | x | 0 | 0.4 | 0.4% | |
Sales to assets ratio | x | 1.3 | 0.2 | 823.0% | |
Return on assets | % | 3.7 | -4.1 | -89.3% | |
Return on equity | % | 5.1 | -7.8 | -65.8% | |
Return on capital | % | 7.7 | -4.8 | -158.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | -912 | 470,328 | -0.2% | |
From Investments | Rs m | -465 | 258,384 | -0.2% | |
From Financial Activity | Rs m | 1,435 | -807,224 | -0.2% | |
Net Cashflow | Rs m | 59 | -78,120 | -0.1% |
Compare MOREPEN LABS With: ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Compare MOREPEN LABS With: DR. REDDYS LAB LINK PHARMA GODAVARI DRU OMKAR PHARMACHEM SOLARA ACTIVE PHARMA SCIENCES
After opening the negative note, Indian share markets Slipped further as the session progressed and ended the day weak.